Cellus is betting that reshaping the terrain around a tumor -- not just going after the tumor itself -- can flip the switch ...

After Eli Lilly, Pfizer, and MSD (Merck & Co. in the U.S. and Canada) walked away from CETP inhibition, Korean pharma Chong ...

Fabry disease is a rare, inherited disorder caused by a mutation in the GLA gene on the X chromosome. This mutation leads to ...

Celltrion’s oncology biosimilars are rapidly solidifying their market dominance in Japan, one of Asia’s largest ...

The influenza pandemic advisory was lifted on Friday. However, due to the increase in Covid-19 infections in neighboring ...

The medical community emphasized the need for internal integration to resolve the government-doctor conflict.“It has been 10 ...

More than a decade after Korea’s National Health Insurance Service (NHIS) filed suit against major tobacco companies over the ...

The Korean Blood Disease and Cancer Association (KBDCA) represented Korea at the Global Myeloma Action Network (GMAN) 2025 ...

A research team at Chung-Ang University Hospital will develop a novel artificial intelligence (AI) algorithm aimed at ...

STGEN Bio, the biopharmaceutical contract manufacturing organization (CMO) under Dong-A Socio Group, said Friday it signed a ...

It took two years, 100,000 signatures, and a wave of public pressure from patients and doctors. Now, Gilead Sciences’ ...

Korea’s Yuhan Corp. is tightening its grip on U.S. rights to its homegrown EGFR inhibitor lazertinib, branded locally as ...